Gleevec patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).


NOVARTIS Treatment of gastrointestinal stromal tumors
Jun, 2022

(1 year, 3 months ago)

Gleevec is owned by Novartis.

Gleevec contains Imatinib Mesylate.

Gleevec has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Gleevec are:

  • US6958335*PED

Gleevec was authorised for market use on 10 May, 2001.

Gleevec is available in capsule;oral dosage forms.

The generics of Gleevec are possible to be released after 19 June, 2022.

Drugs and Companies using IMATINIB MESYLATE ingredient

Market Authorisation Date: 10 May, 2001

Treatment: NA


How can I launch a generic of GLEEVEC before it's drug patent expiration?
More Information on Dosage

GLEEVEC family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic